Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

753.41 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,432
Open 753.41
Bid (Size) 745.68 (1)
Ask (Size) 751.90 (1)
Prev. Close 753.41
Today's Range 753.41 - 753.41
52wk Range 561.65 - 972.53
Shares Outstanding N/A
Dividend Yield 0.60%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Are Diet Drug Companies Over The Hump?
Eli Lilly made a reversal bottom low on Monday after a gap lower. Today’s price action was confirmation. 
Via Talk Markets
Topics Stocks / Equities
Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate
Eli Lilly and Verge Genomics advance ALS drug development with validated targets and a Phase 1B study, part of their $694 million collaboration since 2021. 
Via Benzinga

Performance

YTD
+27.22%
+27.22%
1 Month
-16.85%
-16.85%
3 Month
-20.86%
-20.86%
6 Month
-6.17%
-6.17%
1 Year
+27.14%
+27.14%

More News

Read More
Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
Via Benzinga
LLY Stock Rebounds Amid AI-Driven ALS Research Breakthroughs
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Via The Motley Fool
Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
From Verge Genomics
Via GlobeNewswire
Eli Lilly Unusual Options Activity
Via Benzinga
Top Research Reports For Eli Lilly, PepsiCo & Morgan Stanley
Via Talk Markets
What To Do After The Worst Week For Healthcare Stocks Since March 2020?
Via Talk Markets
Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip?
Via Benzinga
Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%
Via Benzinga
Jim Cramer: Coinbase Is A 'Winner,' Suggests Buying This 'Hated' Big Pharma Stock
Via Benzinga
The Smartest Megacap Growth ETF to Buy With $500 Right Now
Via The Motley Fool
Topics ETFs
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
Via Benzinga
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now
Via The Motley Fool
Goldman Sachs Economist: Weight-Loss Drugs Could Be Key To US Economic Growth
Via Benzinga
Topics Economy
Exposures Economy
Prediction: 3 Stocks That'll Be Worth More Than Tesla 10 Years From Now
Via The Motley Fool
Not-So-Big Pharma
Via Talk Markets
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
Via The Motley Fool
Topics Government
Exposures Political
AskSlim Market Week - Friday, Nov. 15
Via Talk Markets
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
Via Benzinga
Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Via The Motley Fool
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.